Oncología médica

2022

1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

   Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2. Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors (Scientific Reports, (2018), 8, 1, (12746), 10.1038/s41598-018-30836-5)

   Scientific Reports

3. Barriers and facilitators of the EfiKroniK exercise program for people with chronic diseases in Primary Care

   Atencion Primaria, Vol. 54, Núm. 10

4. Bridging the equity gap in patient education: the biliary tract cancer BABEL project

   The Lancet Oncology

5. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

   Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

6. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients

   Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1

7. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

   Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79

8. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study

   Trials, Vol. 23, Núm. 1

9. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

   Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

10. Erratum: TEMPORARY REMOVAL: PO-14: Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients (Thrombosis research PII: S0049-3848(22)00202-X)

    Thrombosis research

11. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution

    Clinical and Translational Oncology, Vol. 24, Núm. 2, pp. 319-330

12. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component

    Gaceta Sanitaria, Vol. 36, Núm. 3, pp. 246-252

13. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

14. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

    European Journal of Internal Medicine, Vol. 105, pp. 30-37

15. Just an Acute Pulmonary Edema? Paraneoplastic Thyroid Storm Due to Invasive Mole

    Case Reports in Oncology, Vol. 15, Núm. 2, pp. 566-572

16. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

17. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study

    Frontiers in Pharmacology, Vol. 13

18. Prediction of chemotoxicity, unplanned hospitalizations and early death in older patients with colorectal cancer treated with chemotherapy

    Cancers, Vol. 14, Núm. 1

19. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

20. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84